Clinical Trial Update: Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating vaccine therapy with high-dose interleukin-2 in metastatic melanoma has completed. The study status is COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Aldesleukin (interleukin-2)

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED